Solu Therapeutics is a biotechnology company pioneering therapies that eliminate disease-driving cells across cancer, immunology, and other therapeutic areas using proprietary CyTAC and TicTAC platforms. Its lead candidate, STX-0712, is a CyTAC designed to target CCR2 and selectively eliminate CCR2-positive malignant monocytes, with an initial focus on CMML and other hematologic malignancies. The company has initiated a first-in-human, open-label, multicenter Phase 1 trial of STX-0712 with a two-part design: Part A dose escalation to determine the maximum tolerated dose and/or minimum effective dose in resistant/refractory CMML, and Part B to evaluate safety, tolerability, recommended Phase 2 dose, and preliminary antitumor activity. Solu presented preclinical ex vivo data at the 2024 ASH Annual Meeting showing robust activity of STX-0712 against CCR2-positive monocytes from CMML patient samples. Proceeds from the recent financing will be used to complete dose escalation and expansion of STX-0712, generate new development candidates including a first-in-class mast cell depletor for immunological diseases, advance additional discovery programs, and explore new applications for the CyTAC and TicTAC platforms. The company was cofounded by Longwood Fund and is based in Boston. Solu Therapeutics is developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity using its proprietary CyTaC (Cytotoxicity Targeting Chimera) platform. CyTaC molecules, licensed from GSK, aim to unlock antibody-intractable cell surface targets and combine the potency of biologics with the broad target binding of small molecules. Characteristics of the platform include unlocking new tumor-associated antigens to eliminate cancer cells, depleting pathogenic immune cells, and extending the half-life of small-molecule antagonists and agonists. The company intends to use the financing to develop the proprietary CyTaC platform and associated drug candidates in-licensed from GSK. Under the license, GSK received equity in Solu and will receive milestones and royalties on products derived from the CyTaC platform. Solu is led by co-founder and CEO David Donabedian, Ph.D., and is based in Boston, MA.

Total raised

$72M

Funding rounds

2

Latest round

Series A

Latest activity

Apr 2025